Dr. Evren Alici is Principal Researcher and Head of the Cell and Gene Therapy Group (CGTG) at the Karolinska Institutet Department of Medicine in Stockholm, Sweden. His primary research focus is on optimizing and clinically adapting strategies to retarget Natural Killer (NK) cells to tumors with limited off-target effects and toxicity profiles. Dr. Alici is also Co-Director of NextGenNK, an international competence center based out of Karolinska Institutet, for the development of next-gen NK cell-based cancer immunotherapies
Dr. Alici’s research focuses on creating novel universal allogeneic NK cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation, and immunology. He is a contributing member of numerous committees and scientific advisory boards providing expertise in immunology, including NK cell biology.
Dr. Alici was on the team that planned, designed, and published the first gene-modified cell therapy research in Sweden. In addition, he was a part of the first-in-man autologous NK cell therapy clinical trial as an advanced therapy medicinal product.
Dr. Alici received his MD, and completed his residency, at Ege University, Turkey. He received his PhD in Hematology from Karolinska Institutet.